Document is current
Any future updates will be listed below
-
Authors
Torre-Cisneros, Julian
Almirante, Benito
Martos, Carmen De La Fuente
Rascado, Pedro
Lletí, Miguel Salavert
Sánchez-García, Miguel
Soriano, Alex
Soriano-Cuesta, Maria Cruz
Gonzalez Calvo, A. Javier
Karas, Andreas
Sarda, Jessica
Verardi, Stefano
Ferrer, Ricard
-
Funding
Funding for this research was provided by:
Shionogi (NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 14 March 2025
First Online: 25 March 2025
Declarations
:
: The study was approved by the institutional review board of Hospital La Princesa, Madrid, on 3 November 2020 (Royal Decree 957/2020), which served as central reference ethics committee. The study was compliant with all legal and regulatory requirements, the International Conference on Harmonisation Good Clinical Practice E6 guidelines and the Declaration of Helsinki.
: According to Spanish regulations, the informed consent for participants was waived by the regulator because patients completed their treatment prior to initiation of this retrospective study and the study represented no harm for the participants.
: Not applicable.
: Julian Torre-Cisneros has received educational grants and fee for advisory activities from Shionogi, Pfizer, MSD, Menarini; and unrestricted research grants from Pfizer and MSD. Benito Almirante received honoraria from Shionogi & Co., Ltd., Osaka, Japan, for participation in this study. Carmen De La Fuente Martos received honoraria from Shionogi & Co., Ltd., Osaka, Japan, for participation in this study. Pedro Rascado has received educational grants and consultancy fees for advisory activities from Pfizer, MSD, Shionogi, and Menarini. Miguel Salavert Lletí has received honoraria for lectures and advisory boards from Angelini, Janssen, Menarini, MSD, Pfizer, Shionogi and Viatris, and educational grants from Gilead and Tedec-Meiji Farma. Miguel Sánchez-García received speaker fees from Shionogi & Co., Spain. Maria Cruz Soriano-Cuesta has received grants for attending medical courses and conferences, and/or received fees for consulting or educational programs from Pfizer, Astellas, MSD, Shionogi, Menarini, Gilead, Mundipharma, and Viatris.Alex Soriano has received honoraria for lectures and advisory boards from Shionogi, Pfizer, Menarini, Angelini, Advance Pharma and Gilead, and grants from Pfizer and Gilead. Ricard Ferrer has received honoraria for lectures from Gilead, Menarini, MSD, Shionogi, and ThermoFisher; consulting fees from Cytosorbent, Inoterm, and Pfizer; and holds stocks or stock options from Grifols. Jessica Sarda, A. Javier Gonzalez Calvo, Stefano Verardi, Andreas Karas are employees of Shionogi.
